Inspired Reports Third Quarter 2025 Results GlobeNewswire November 05, 2025 Strong Interactive Momentum and Strategic Evolution Position Inspired for Growth and Margin Expansion Revenue of $86.2 million, up 12% over prior year, driven primarily by record Interactive revenue, up 48% year-over-year Net Operating Income of $9.7 million, Net Loss of $1.9 million and Adjusted Net […]
Sportradar Reports Third Quarter Financial Results, Raises Full Year 2025 Outlook and Announces Increase in Share Repurchase Program to $300 Million GlobeNewswire November 05, 2025 Third Quarter 2025 Highlights Revenue increased 14% to EUR292 million Generated profit for the period of EUR22 million, 7.7% as a percentage of revenue Adjusted EBITDA1 increased 29% to EUR85
Jaya Biosciences Receives U.S. Patent for Novel Methods of Treating Neurological Diseases, Including Alzheimer's Disease, Expanding its Global Intellectual Property Portfolio U.S. patent grant broadens protection and strengthens Jaya Biosciences' leadership in developing CNS-directed therapies for genetically defined neurodegenerative diseases GlobeNewswire November 05, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — Jaya
BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters GlobeNewswire November 05, 2025 Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 05,
Aben Gold Receives Class 1 Quartz Approval to Conduct Exploration at Justin Gold Project GlobeNewswire November 05, 2025 Vancouver, BC, Nov. 05, 2025 (GLOBE NEWSWIRE) — Aben Gold Corp. (TSX-V: ABM) (OTCID: ABNAF) (Frankfurt: ML1) (“Aben” or “the Company”) announces that it has received a Class 1 Quartz Approval from the Liard First Nations, Ross
Sachem Capital Reports Third Quarter 2025 Results GlobeNewswire November 05, 2025 – Company to Host Webcast and Conference Call – BRANFORD, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) (the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update GlobeNewswire November 05, 2025 Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degrader entered non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers
BioCryst to Present at Upcoming Investor Conference GlobeNewswire November 05, 2025 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 12:00 p.m. ET. The link to the
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek(R) 2025 GlobeNewswire November 05, 2025 The Company's investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of BMF-650 in healthy obese patients is currently
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference GlobeNewswire November 05, 2025 WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced